Indications

Inflammatory Bowel Disease: Crohn’s disease (CD), ulcerative colitis (UC).

Rheumatoid arthritis (RA).

Other autoimmune diseases driven by aberrant TL1A and IL23 pathways.

Target Patients

Provides a novel, enhanced therapeutic option for patients with inadequate response, loss of response, or intolerance to conventional therapies or singletarget biologics.

Mechanism of Action

Neutralizes TL1A: Reduces differentiation and activation of Th1/Th17 cells, downregulating intestinal and systemic inflammatory responses.

Neutralizes IL23p19: Precisely binds the p19 subunit of IL23, thereby inhibiting the production of downstream proinflammatory cytokines such as IL17 and IL22.

Synergistic Effect: Dualtarget synergy enables more comprehensive immune pathway modulation, with the potential to overcome the efficacy limitations of singletarget therapies.

Administration

Route: Subcutaneous injection via prefilled syringe or autoinjector pen.

Frequency: Once monthly or less frequent dosing, as per clinical protocol design.

Key Advantages

Dual Precision Targeting: Utilizing an advanced nanobodybased bispecific design, the drug simultaneously inhibits two core inflammatory pathways—TL1A and IL23—covering a broader range of disease drivers and offering potentially superior efficacy compared to singletarget agents.

Enhanced Tissue Penetration: With a molecular weight only half that of traditional bispecific antibodies, it exhibits improved tissue permeability, helping to elevate drug concentrations in inflamed tissues such as the intestinal mucosa, skin, or joints.

Potentially Favorable Safety Profile: The product is highly humanized, forms smaller immune complexes than conventional TL1A monoclonal antibodies, and carries a low risk of immunogenicity. Synergistic dualtarget action may allow lower clinically effective doses, reducing the risk of infections associated with systemic immunosuppression.

Patient Convenience: Designed for longacting subcutaneous administration, it reduces the frequency of healthcare visits and improves quality of life.

Cost Efficiency: Bispecific antibody production reaches 12 g/L, offers excellent stability for longterm storage at 2–8 °C, and delivers stronger market competitiveness.